Overview

To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus

Status:
Completed

Trial end date:
2017-01-01

Target enrollment:

Participant gender:

Summary

To demonstrate the comparative effectiveness of 12 months of Lucentis (ranibizumab) in patients with well controlled compared to those with poorly controlled diabetes using an PRN treatment schedule.

Phase:

Phase 3

Details

Lead Sponsor:

Marsden Eye Specialists

Treatments:

Ranibizumab